A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC 681239) and Bendamustine in Patients With Untreated Follicular Lymphoma

Trial Profile

A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC 681239) and Bendamustine in Patients With Untreated Follicular Lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2018

At a glance

  • Drugs Bortezomib (Primary) ; Bendamustine; Ofatumumab
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Apr 2018 Status changed from active, no longer recruiting to completed.
    • 12 Dec 2017 Primary endpoint (Complete response rate) has not been met, according to results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top